14. The immunogenic composition of claim 13, wherein the at least one adjuvant is selected from the group consisting of methylated CpG oligodeoxynucleotides (CpG ODN), aluminum hydroxide (alum), MPL-monophosphate lipid A, flagellin, cytokines, and toxins.

15. The immunogenic composition of claim 14, wherein the toxin is *E. coli* heat-labile enterotoxin and/or cholera toxin.

16. The immunogenic composition of claim 13, wherein the at least one adjuvant is an emulsions.

17. Use of ~~A~~an immunogenic composition comprising purified outer membrane vesicles derived from at least one species of *Burkholderia* in the manufacture of a medicament for protecting a subject against infection caused by at least one species of *Burkholderia*, wherein administration of the ~~immunogenic composition~~ medicament provides protection against infection.

18. The ~~immunogenic composition~~use of claim 17, wherein the ~~immunogenic composition~~medicament is to be administered subcutaneously, intranasally, and/or intramuscularly.

19. The ~~immunogenic composition~~use of claim 17, wherein administration of the medicament ~~immunogenic composition~~ produces protective humoral and cellular immunity to at least one species of *Burkholderia*.

20. The ~~immunogenic composition~~ use of claim 19, wherein the protective humoral immunity in the subject comprises production of IgG and/or IgA specific to the administered outer membrane vesicles.

21. The ~~immunogenic composition~~ use of claim 20, wherein production of IgG specific to the administered outer membrane vesicles increases by at least about 1-log when the medicament ~~immunogenic composition~~ is subsequently administered.

22. The ~~immunogenic composition~~ use of claim 20, wherein the IgG specific to the administered outer membrane vesicles comprises IgG1 and/or IgG2a.

23. The ~~immunogenic composition~~ use of claim 19, wherein the protective cellular immunity in the subject comprises activation of memory T cells in response to the administered outer membrane vesicles.

24. The ~~immunogenic composition~~ use of claim 23, wherein activation of memory T cells comprises production of interferon-gamma (IFN-γ) by Th1 memory cells.

25. The ~~immunogenic composition~~ use of claim 19, wherein administration of the ~~immunogenic composition~~ medicament provides protection when the subject is subsequently exposed to an aerosol challenge comprising at least one species of *Burkholderia*.

26. The ~~immunogenic composition~~ use of claim 25, wherein the aerosol challenge comprises a lethal dose of the at least one species of *Burkholderia*.

27. The ~~immunogenic composition~~ use of claim 19, wherein the subject is protected against infection caused by *Burkholderia pseudomallei* and/or *Burkholderia mallei*, and

wherein the ~~immunogenic composition~~ medicament comprises purified outer membrane vesicles derived from at least *Burkholderia pseudomallei* and/or *Burkholderia mallei*.

28. Use of ~~A~~an immunogenic composition according to claim 9 in the manufacture of a medicament for inducing an immune response to at least one species of *Burkholderia* in a subject, wherein the ~~immunogenic composition~~ medicament is to be administered to a subject in an amount effective to elicit production of antibodies specific to the at least one species of *Burkholderia*.

29. The ~~immunogenic composition~~ use of claim 28, wherein the ~~immunogenic composition~~ medicament is produced by:

a. growing a culture of Gram-negative bacteria;

b. subjecting said culture to centrifugation, thereby obtaining a cell pellet and a supernatant fraction;

c. harvesting outer membrane vesicles from the supernatant fraction;

d. purifying the outer membrane vesicles harvested from step (c) by gradient centrifugation; and

e. collecting the outer membrane vesicles purified from step (d).

30. The ~~immunogenic composition~~use of claim 29, wherein the gradient centrifugation of step (d) comprises high-speed centrifugation followed by density-gradient centrifugation.

31. Use of ~~A~~an immunogenic composition comprising purified outer membrane vesicles derived from at least one species of *Burkholderia* in the manufacture of a medicament for preventing respiratory infection in a subject wherein the respiratory infection is caused by at least one species of *Burkholderia*, wherein the ~~immunogenic composition~~ medicament is to be administer~~eding~~ to the subject, and wherein administration of the ~~immunogenic composition~~ medicament prevents at least one symptom of said respiratory infection.

32. The ~~immunogenic composition~~use of claim 31, wherein the ~~immunogenic composition~~ medicament is to be administered subcutaneously, intranasally, and/or intramuscularly.

33. The ~~immunogenic composition~~ use of claim 31, wherein the respiratory infection is caused by *Burkholderia pseudomallei* and/or *Burkholderia mallei*, and

wherein the ~~immunogenic composition~~ medicament comprises purified outer membrane vesicles derived from at least *Burkholderia pseudomallei* and/or *Burkholderia mallei*.

34. Use of ~~A~~an immunogenic composition comprising purified outer membrane vesicles derived from at least one species of *Burkholderia* in the manufacture of a medicament for preventing meliodosis in a subject wherein the meliodosis is caused by at least one species of *Burkholderia*, wherein the ~~immunogenic composition~~ medicament is to be

administered to the subject, and wherein administration of the ~~immunogenic composition~~ medicament produces immunity to said at least one species of *Burkholderia*.

35. The ~~immunogenic composition~~use of claim 34, wherein the ~~immunogenic composition~~ medicament is to be administered subcutaneously, intranasally, and/or intramuscularly.

36. The ~~immunogenic composition~~ use of claim 34, wherein the immunity in the subject is protective humoral and cellular immunity.

37. The ~~immunogenic composition~~ use of claim 34, wherein the protective humoral immunity in the subject comprises production of IgG and/or IgA specific to the administered outer membrane vesicles when the subject is exposed to at least one species of *Burkholderia* after administration of the ~~immunogenic composition~~medicament.

38. The ~~immunogenic composition~~ use of claim 34, wherein the protective cellular immunity in the subject comprises activation of memory T cells in response to the administered outer membrane vesicles.

39. The ~~immunogenic composition~~ use of claim 38, wherein activation of memory T cells comprises production of interferon-gamma (IFN-γ) by CD4+ and/or CD8+ T cells.

40. The ~~immunogenic composition~~ use of claim 34, wherein administration of the ~~immunogenic composition~~ medicament provides protection when the subject is subsequently exposed to an aerosol challenge comprising the at least one species of *Burkholderia*.

41. The ~~immunogenic composition~~ use of claim 34, wherein the meliodosis is pneumonic meliodosis and/or septicemic meliodosis.

42. The ~~immunogenic composition~~ use of claim 34, wherein the meliodosis is caused by *Burkholderia pseudomallei*, and

wherein the ~~immunogenic composition~~ medicament comprises purified outer membrane vesicles derived from at least *Burkholderia pseudomallei*.

43. The ~~immunogenic composition~~ use of claim 34, wherein the ~~immunogenic composition~~ medicament further comprises at least one adjuvant.

44. The ~~immunogenic composition~~ use of claim 43, wherein the at least one adjuvant is selected from the group consisting of methylated CpG oligodeoxynucleotides (CpG ODN), aluminum hydroxide (alum), MPL-monophosphate lipid A, flagellin, cytokines, and toxins.

45. The ~~immunogenic composition~~ use of claim 44, wherein the toxin is *E. coli* heat-labile enterotoxin and/or cholera toxin.

46. The ~~immunogenic composition~~ use of claim 43, wherein the at least one adjuvant is an emulsions.

47. Use of ~~A~~an immunogenic composition comprising purified outer membrane vesicles derived from at least one species of *Burkholderia cepacia* complex in the manufacture of a medicament for preventing respiratory infection in a subject wherein the respiratory infection is caused by at least one species of *Burkholderia cepacia* complex, wherein the ~~immunogenic composition~~ medicament is to be administered to the subject, wherein administration of the ~~immunogenic composition~~ medicament produces immunity to said at least one species of *Burkholderia cepacia* complex, and wherein administration of the ~~immunogenic composition~~ medicament prevents at least one symptom of said respiratory infection.

48. The ~~immunogenic composition~~ use of claim 47, wherein the immunity in the subject is protective humoral and/or cellular immunity.

49. The ~~immunogenic composition~~ use of claim 47, wherein the respiratory infection is rapidly fatal pulmonary infection.

50. The ~~immunogenic composition~~ use of claim 47, wherein the subject is afflicted with cystic fibrosis.

51. The ~~immunogenic composition~~ use of claim 47, wherein the respiratory infection is caused by *Burkholderia cenocepacia* and/or *Burkholderia multivorans*, and

wherein the ~~immunogenic composition~~ medicament comprises purified outer membrane vesicles derived from *Burkholderia cenocepacia* and/or *Burkholderia multivorans.*